CD274 and neoplasm: For example, the EGFR-CD3-PD-L1 Multi-TAC not only bridges T cells and dendritic cells to enhance anti-tumor responses but also blocks PD-L1–mediated immunosuppression, addressing TME complexity in solid tumors (Fig. 6).